Nezebi (Oxymetazoline Hydrochloride)

Oxymetazoline Hydrochloride, the active ingredient in Nezebi, is an alpha‑adrenergic agonist presented as a nasal spray for intranasal use. It relieves nasal congestion associated with the common cold, sinusitis and allergic rhinitis by constricting blood vessels in the nasal mucosa.

GNH USA supplies Nezebi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers.

Oxymetazoline is used as a topical nasal decongestant to alleviate swelling of the nasal passages.

- Common cold nasal congestion: reduces mucosal swelling to improve airflow. - Sinusitis-related congestion: decreases nasal passage edema, facilitating sinus drainage. - Allergic rhinitis: alleviates nasal blockage caused by allergic inflammation.

Oxymetazoline may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing. - Headache.

Serious or Rare Side Effects: - Rebound nasal congestion with prolonged use. - Elevated blood pressure or hypertension. - Cardiac arrhythmias or tachycardia. - Severe nasal ulceration.

When using Oxymetazoline nasal spray, several safety considerations should be observed.

- Duration of use: limit to no more than three consecutive days to avoid rebound congestion. - Pregnancy and lactation: consult a healthcare professional before use, as safety data are limited. - Cardiovascular disease: use with caution in patients with hypertension or heart disease. - Pediatric use: not recommended for children under six years of age. - Concomitant sympathomimetic drugs: avoid using with other nasal decongestants or systemic stimulants. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Oxymetazoline can interact with other medications, influencing its safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may cause excessive hypertensive response. - Other topical nasal decongestants: risk of additive vasoconstriction and rebound congestion. - Systemic sympathomimetic agents (e.g., pseudoephedrine): can amplify cardiovascular effects.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: may reduce their efficacy, requiring blood pressure monitoring. - Beta‑blockers: possible alteration of heart rate response. - Tricyclic antidepressants: may increase risk of hypertension. - Herbal stimulants (e.g., ephedra): monitor for additive sympathomimetic effects.